Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) Given Average Rating of “Moderate Buy” by Analysts

Shares of Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) have been given a consensus recommendation of “Moderate Buy” by the twelve analysts that are covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $13.50.

Several research analysts recently weighed in on the stock. Royal Bank Of Canada boosted their price target on shares of Aveanna Healthcare from $10.00 to $16.00 and gave the stock an “outperform” rating in a report on Monday, August 24th. Barclays lifted their target price on shares of Aveanna Healthcare from $9.50 to $15.00 and gave the stock an “overweight” rating in a research report on Friday. BMO Capital Markets boosted their target price on Aveanna Healthcare from $10.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, August 14th. Wall Street Zen downgraded Aveanna Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Thursday, July 2nd.

Insiders Place Their Bets

In other news, major shareholder Robert M. Williams, Jr. sold 2,250,000 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $11.50, for a total transaction of $25,875,000.00. Following the transaction, the insider owned 12,315,892 shares of the company’s stock, valued at $141,632,758. This represents a 15.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Paul R. Vigano sold 2,250,000 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $11.50, for a total transaction of $25,875,000.00. Following the sale, the insider directly owned 12,315,892 shares in the company, valued at approximately $141,632,758. This trade represents a 15.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 79,746,745 shares of company stock valued at $773,117,091. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC increased its holdings in shares of Aveanna Healthcare by 21.2% in the 1st quarter. AQR Capital Management LLC now owns 26,280 shares of the company’s stock worth $142,000 after buying an additional 4,602 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Aveanna Healthcare by 8.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 339,853 shares of the company’s stock worth $1,842,000 after acquiring an additional 25,974 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Aveanna Healthcare by 522.0% during the 1st quarter. Jane Street Group LLC now owns 75,081 shares of the company’s stock worth $407,000 after acquiring an additional 63,010 shares during the last quarter. Creative Planning grew its position in Aveanna Healthcare by 15.1% in the second quarter. Creative Planning now owns 47,025 shares of the company’s stock worth $246,000 after acquiring an additional 6,171 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Aveanna Healthcare by 65.0% in the second quarter. JPMorgan Chase & Co. now owns 158,265 shares of the company’s stock worth $828,000 after acquiring an additional 62,348 shares in the last quarter. 87.96% of the stock is currently owned by hedge funds and other institutional investors.

Aveanna Healthcare Price Performance

Shares of AVAH opened at $13.32 on Monday. The stock has a market cap of $2.91 billion, a P/E ratio of 10.83, a P/E/G ratio of 0.84 and a beta of 1.90. The business’s fifty day moving average is $10.18 and its 200 day moving average is $8.11. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 4.47. Aveanna Healthcare has a 12-month low of $5.93 and a 12-month high of $14.00.

Aveanna Healthcare (NASDAQ:AVAH) last released its quarterly earnings results on Thursday, August 13th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.17 by $0.05. The business had revenue of $670.48 million during the quarter, compared to the consensus estimate of $638.61 million. Aveanna Healthcare had a return on equity of 80.70% and a net margin of 10.56%. Sell-side analysts anticipate that Aveanna Healthcare will post 0.75 earnings per share for the current fiscal year.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.